TrialLeukemia2020

Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group.

Dennis A Eichenauer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.